All time high of biologics sales in 2017 driven by cancer antibodies and innovative anti-inflammatory antibodies
- Category: Press Room
- Published on Monday, 12 March 2018 18:00
- Hits: 3190
STUTTGART, Germany I March 12, 2017 I Global sales of branded recombinant therapeutic antibodies and proteins in the calendar year 2017 reached an all time high of more than US$ 188 bln, as reported by La Merie Publishing. The increase by 11.9% compared with the previous year was driven by the double-digit growth of cancer antibodies and new anti-inflammatory antibodies, but also by the favorable currency exchange rate. 2017 was also the year of the anti-TNF antibody Humira which posted global sales of US$ 18.9 bln. AbbVie was able to defend Humira in the first litigation by postponing US market entry of Amgen’s Humira biosimilar to 2023, but Amgen will enter the European Humira market in October 2018. The anti-TNF antibodies Enbrel and Remicadepd continued their slow decline in sales by increasingly strong biosimilar competition.
Sales of the anti-PD-1 antibodies Opdivo and Keytruda combined grew by 59% to US$ 9.6 bln in the year 2017. Two-thirds of all biologics sales can be attributed to therapeutic antibodies. Insulins and insulin analogues are the strongest class of therapeutics proteins with sales of US$ 22 bln in 2017. Insulins as well as coagulation factors face a major shake-up mainly by entry of innovative products, but also by increasing sales of insulin biosimilars.
La Merie Publishing released on March 9, 2018 the 12th edition of its report about sales of Blockbuster Biologics. A total of 45 biologic therapeutics reached blockbuster status with 2017 sales exceeding US$ 1 bln: 27 antibodies and 18 proteins. Fourteen new biologics with sales data were included for the first time in this compilation. Ten biologics reached global sales in 2017 of more than US$ 5 bln. Three biologics were new in the blockbuster biologics list. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.
The report „Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins“ can be acquired at La Merie Publishing’s News Center and Online Store www.PipelineReview.com: https://www.pipelinereview.com/index.php/store-online/blockbuster-biologics-2017-sales-of-recombinant-therapeutic-antibodies-proteins-detail
This report prepared by La Merie Publishing provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2017. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 8, 2017. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).
Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2017 sales higher than US$ 1 bln. Another ranking list was prepared for TOP 30 companies according to biologics sales in 2017 and the percentage of antibody sales of total biologics sales.
About La Merie
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.
SOURCE: La Merie Publishing